Your Cart Item
Reports Within

Parameters

Reports Within:

Parameter Include:

Requisites
Measures

Number of red blood cells in the blood

Identifies

Red blood cell disorders

Measures: Number of red blood cells in the blood

Identifies: Red blood cell disorders

60
Mins

Homes

1M
Happy

Customers

4.9
Google

Rating

Certified

Labs

What is the maximum days the report can be obtained for the test

The maximum days for obtaining the report for the test CMML Risk Stratification Gene Panel is 14 days.

What are the prerequisites for the test CMML Risk Stratification Gene Panel

  • Diagnosis of Chronic Myelomonocytic Leukemia (CMML)
  • Validated bone marrow aspirate or peripheral blood sample
  • Complete blood count (CBC) and peripheral blood smear
  • Recent molecular testing results, if available
  • Physician's order or requisition form

What are the measure values for the test CMML Risk Stratification Gene Panel

  • JAK2 V617F Mutation: Positive or Negative
  • ASXL1 Mutation: Presence or Absence
  • EZH2 Mutation: Presence or Absence
  • DNMT3A Mutation: Presence or Absence
  • NRAS Mutation: Presence or Absence
  • TP53 Mutation: Presence or Absence

What does this test CMML Risk Stratification Gene Panel identify?

The CMML Risk Stratification Gene Panel identifies specific genetic mutations that are associated with the risk of developing Chronic Myelomonocytic Leukemia (CMML). These mutations can help determine the prognosis and guide treatment decisions for patients with CMML.

The panel typically includes genes such as:

  • TET2: Mutations in this gene are common in CMML and are associated with a poorer prognosis.
  • SRSF2: Mutations in this gene are also common in CMML and may indicate a higher risk of progression to acute myeloid leukemia.
  • RAS: Mutations in RAS genes (such as NRAS and KRAS) are associated with a higher risk of aggressive disease.
  • CBL: Mutations in this gene are associated with a poor prognosis in CMML.

By analyzing these genetic mutations, healthcare providers can better assess the risk of disease progression and tailor treatment plans to each individual patient.

Why is this test CMML Risk Stratification Gene Panel taken?

This test is taken to determine the risk stratification of Chronic Myelomonocytic Leukemia (CMML) based on genetic mutations. CMML is a type of leukemia that affects the bone marrow and blood. By analyzing specific genes associated with CMML, such as ASXL1, SRSF2, and TET2, healthcare providers can better understand the prognosis and treatment options for patients with this condition. The results of this gene panel test can help guide personalized treatment plans and monitor disease progression.

No FAQs available.

Customer Google Rating